



Dear Community,

December 22, 2020

Please allow me to share some of our reflections and observations from our engagement with you, as we come to the end of an unforgettable year. I'd like also to share with you a document designed hopefully to answer the questions on your mind regarding our clinical program, UNITE-CNM.

Our Program:

We have begun clinical development of our investigational product candidate DYN101 with a Phase 1/2 clinical trial and have dosed the first patients. The goal of UNITE-CNM is to learn about the safety and tolerability of DYN101 in patients aged 16 or older, with X-linked myotubular myopathy, or XLCNM (*MTM1 gene mutation*), or autosomal dominant CNM, or ADCNM (*DNM2 gene mutation*). We understand that you are anxious to hear about our progress in this study, but we will be limited in what we can share as part of the regulatory guidelines established for clinical trials. More information about the trial can be found in a FAQ document in multiple languages, which you'll find [here](#). We invite you to check back periodically for updates on our Website.

Our Connection with you:

In 2020, we brought on a Patient Advocacy lead for Dynacure named Lori Gorski. Lori has been very fortunate to hear many first-hand stories from families in the community about their daily lives and hopes for the future. We heard resoundingly from the community that caring for a loved one with any form of CNM has become profoundly more challenging during the COVID pandemic. The caregivers we have spoken with are the experts in these diseases, their focus on the well-being of their loved ones is relentless and they are real-world examples of that heroes are all around us. We intend to continue to reach out to additional families throughout next year as we learn from each of these encounters.

We also had the opportunity in 2020 to participate in several patient meetings, to answer your questions and to hear your feedback for us. We have valued this engagement with you and are grateful to the leaders of the Advocacy organizations for including us. If you are not already part of the global patient advocacy community, I encourage you to seek out the advocacy organizations in your region as the best way to stay connected and informed as a community.

Our Admiration and Hope:

Finally, while we have all faced a challenging year, we know that 2020 has been especially difficult for all people living with myotubular and centronuclear myopathies and their caregivers. Your resiliency is inspiring, and we are humbled and grateful to be a part of this journey with you. Please know that we remain focused on advancing our clinical program and identifying new ways to better understand and support your community around the world. We are hopeful for better times to come.

On behalf of each one of us at Dynacure, we wish you a warm holiday season and Happy New Year.

Stephane van Rooijen
Chief Executive Officer
Dynacure

